View larger
H5N1 Influenza-A Virus Vietnam 1203/04 Recombinant ( H5N1 Vietnam )
DescriptionRecombinant Full-Length H5N1 A/Vietnam/1203/04 is glycosylated with N-linked sugars, produced using baculovirus and when processed under denaturing conditions splits into the HA1 and HA2 domains which are approximately 45,000 and 25,000
Data sheet
| Formulation | The Recombinant H5N1 A/Vietnam/1203/04 solution contains 10mM Sodium Phosphate, pH 7.1, 0.005% Tween-20 and 150mM NaCl. |
| Purity | Greater than 90.0% as determined byAnalysis by SDS-PAGE, HA1 and HA2 bands are observed using SDS-PAGE under reducing conditions. |
| Description | Recombinant Full-Length H5N1 A/Vietnam/1203/04 is glycosylated with N-linked sugars, produced using baculovirus and when processed under denaturing conditions splits into the HA1 and HA2 domains which are approximately 45,000 and 25,000 Daltons respectively H5N1 A/Vietnam/1203/04 accession number is ISDN38687. |
| Protein Background | Influenza A virus subtype H5N1 is a subtype of the Influenza A virus. Subtype H5N1 is commonly known as avian influenza or bird flu. H5N1 may cause more than one influenza pandemicas it is expected to continue mutating in birds. The dominant strain of HPAI A (H5N1) evolved creating the Z genotype. It has also been called Asian lineage HPAI/A/H5N1 which is divided into 2 antigenic clades. "Clade 1 includes human and bird isolates from Vietnam, Thailand, and Cambodia and bird isolates from Laosand Malaysia. Clade 2 viruses were first identified in bird isolates from China, Indonesia, Japan, and South Korea before spreading westward to the Middle East, Europe, and Africa. |
| Expression host | Baculovirus Insect Cells. |
| Reagent Appearance | Sterile Filtered colorless solution. |
| Stability | H5N1 A/Vietnam/1203/04 Recombinant should be stored at 4°C. Do not freeze! |
| Amino acid sequence | V K M E K I V L L F A I V S L V K S D Q I C I G Y H A N N S T E Q V D T I M EK N V T V T H A Q D I L E K K H N G K L C D L D G V K P L I L R D C S V A GW L L G N P M C D E F I N V P E W S Y I V E K A N P V N D L C Y P G D F N DY E E L K H L L S R I N H F E K I Q I I P K S S W S S H E A S L G V S S A C PY Q G K S S F F R N V V W L I K K N S T Y P T I K R S Y N N T N Q E D L L VL W G I H H P N D A A E Q T K L Y Q N P T T Y I S V G T S T L N Q R L V P R IA T R S K V N G Q S G R M E F F W T I L K P N D A I N F E S N G N F I A P EY A Y K I V K K G D S T I M K S E L E Y G N C N T K C Q T P M G A I N S S MP F H N I H P L T I G E C P K Y V K S N R L V L A T G L R N S P Q R E R R RK K R G L F G A I A G F I E G G W Q G M V D G W Y G Y H H S N E Q G S GY A A D K E S T Q K A I D G V T N K V N S I I D K M N T Q F E A V G R E F NN L E R R I E N L N K K M E D G F L D V W T Y N A E L L V L M E N E R T L DF H D S N V K N L Y D K V R L Q L R D N A K E L G N G C F E F Y H K C D NE C M E S V R N G T Y D Y P Q Y S E E A R L K R E E I S G V K L E S I G I YQ I L S I Y S T V A S S L A L A I M V A G L S L W M C S N G S L Q C R I C I. |
| Product Description | Immunoreactive with all sera of HIV-1 infected individuals. |